{"disease":{"id":"thrombotic-microangiopathy","name":"thrombotic microangiopathy"},"drugs":{"marketed":[{"drug_id":"narsoplimab","indication_name":"hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yartemlea","generic_name":"NARSOPLIMAB","company_name":"Omeros Corp","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Narsoplimab works by targeting and modulating the immune system to prevent damage to blood vessels."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT04543591","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04845022","title":"Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome","phase":"","overall_status":"UNKNOWN","enrollment_count":81,"lead_sponsor_name":"Jubilee Mission Medical College and Research Institute","has_results":false},{"nct_id":"NCT07279610","title":"N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":44,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04557735","title":"Study of Ravulizumab in Pediatric Participants With HSCT-TMA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05743400","title":"Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07347990","title":"Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT04743804","title":"Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05148299","title":"A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT06182410","title":"Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04247906","title":"Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Omeros Corporation","has_results":false},{"nct_id":"NCT02355782","title":"OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Michal Nowicki","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}